The Pan American Journal of Public Health published a letter from Professor Erika Lietzan, in which she responds to an article about Colombia’s pathways for approval of biosimilar biologics. A 2014 presidential decree in Colombia allowed for three pathways to market for biologics, and the earlier article, written by the country’s Minister of Health and Social Protection and his colleagues,…
Category: Center for Intellectual Property and Entrepreneurship ⋅ Page 4
Professor Lietzan testifies before the U.S. House of Representatives Judiciary Committee
Professor Erika Lietzan testified before the House of Representatives Judiciary Committee on July 27, 2017 in a hearing addressing Antitrust Concerns and the FDA Approval Process. Testimony to House of Representatives Judiciary Committee –…